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Abstract: Pneumonia remains a major cause of child
death globally, and improving antibiotic treatment rates is
a key control strategy. Progress in improving the global
coverage of antibiotic treatment is monitored through
large household surveys such as the Demographic and
Health Surveys (DHS) and the Multiple Indicator Cluster
Surveys (MICS), which estimate antibiotic treatment rates
of pneumonia based on two-week recall of pneumonia by
caregivers. However, these survey tools identify children
with reported symptoms of pneumonia, and because the
prevalence of pneumonia over a two-week period in
community settings is low, the majority of these children
do not have true pneumonia and so do not provide an
accurate denominator of pneumonia cases for monitoring
antibiotic treatment rates. In this review, we show that the
performance of survey tools could be improved by
increasing the survey recall period or by improving either
overall discriminative power or specificity. However, even
at a test specificity of 95% (and a test sensitivity of 80%),
the proportion of children with reported symptoms of
pneumonia who truly have pneumonia is only 22% (the
positive predictive value of the survey tool). Thus,
although DHS and MICS survey data on rates of care
seeking for children with reported symptoms of pneu-
monia and other childhood illnesses remain valid and
important, DHS and MICS data are not able to give valid
estimates of antibiotic treatment rates in children with
pneumonia.
This paper is part of the PLOS Medicine ‘‘Measuring Coverage in
MNCH’’ Collection.
Introduction
Pneumonia has been the largest single cause of child death over
the 2000–2015 Millennium Development Goal period [1,2], and
despite large falls in global under-five mortality, pneumonia
remains the major single cause of child death in the post-neonatal
period [3]. Recent estimates suggest that pneumonia accounted for
about 0.32 million deaths in the first month of life and 1.1 million
post-neonatal child deaths in 2010—over 14% of all child deaths
under five years of age. These estimates, together with an analysis
of the rate of fall of cause-specific child mortality, suggest that
efforts to reduce child deaths from pneumonia will have to be
accelerated if the target of Millennium Development Goal 4—to
reduce child mortality by two-thirds between 1990 and 2015—is
to be met [3]. Moreover, pneumonia accounts for a substantial
percentage of all paediatric out-patient attendances, in-patient
admissions, and antibiotic prescriptions in health services in low-
and middle-income countries (bacterial pneumonia is the major
cause of severe episodes of pneumonia and death from pneumo-
nia) and so places a large burden on these health services and on
the families involved [4].
Several effective interventions are available to tackle the
challenge of childhood pneumonia, as recently summarised in a
series of review articles commissioned as part of the Global Action
Plan for the Prevention and Control of Pneumonia [4,5]. Key
amongst these interventions are immunisation and correct case
management of young children with pneumonia who present to
trained health workers. Both of these strategies have been shown
to be effective through controlled trials [6,7]. However, although
there are robust and accurate mechanisms to measure the
performance and progress of immunisation programmes, there
are no well-established monitoring methods for (community) case
management programmes.
The two major interventions that reduce mortality from
bacterial pneumonia are antibiotic treatment (for all cases) and
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oxygen therapy (in those children who have hypoxaemia). Thus,
programme monitoring of case management programmes at
(sub-) national, regional, and global levels requires the accurate
measurement of the percentage of children with pneumonia in a
defined population who receive antibiotic therapy.
Unfortunately, caregivers of sick children with pneumonia often
do not seek antibiotic treatment from trained health providers.
Findings from eight studies from seven low- and middle-income
countries that interviewed caregivers of young children with
pneumonia suggest that caregivers sought care from an appropri-
ate health provider who could give correct antibiotic treatment in
only about half of pneumonia episodes [8–15]. These findings
highlight the need for community-based rather than hospital-
based studies to measure antibiotic treatment rates in children with
pneumonia if a true population-based estimate is to be made
(rather than a biased estimate based on the unrepresentative
subgroup of children whose caregivers seek care). Furthermore,
the availability of first and second line antibiotics within first level
health facilities in low- and middle-income countries may be poor
and may vary markedly across institutions, again suggesting that a
population-based survey is required.
Programme monitoring therefore needs to identify a represen-
tative group of children who have recently had an episode of
pneumonia and then investigate what proportion of these children
received (correct) antibiotic treatment. In recent years, the
Demographic and Health Surveys (DHS) and the United Nations
Children’s Fund Multiple Indicator Cluster Surveys (MICS) have
undertaken these processes in low- and middle-income countries.
Specifically, these surveys ask caregivers to recall symptoms and
signs of pneumonia in their children, which provides the
denominator of pneumonia cases, and collect data from caregivers
on antibiotic treatments received, which allows the antibiotic
treatment rate to be estimated. In this review, which is part of the
PLOS Medicine ‘‘Measuring Coverage in MNCH’’ Collection, we
consider how our current understanding of the epidemiology of
childhood pneumonia can inform the design and interpretation of
surveys seeking to monitor antibiotic treatment rates.
Disease Prevalence and Survey Sample Size
It is reasonable to assume that the data used to monitor
antibiotic treatment rates will not be widely available from cohort
studies but will be measured in cross-sectional surveys. The power
of such surveys can be roughly estimated by assuming that there is
no seasonality of pneumonia incidence and that the duration of
pneumonia symptoms is one week on average. A cross-sectional
survey of 1,000 young children that enquires about symptoms of
pneumonia that were present in the past two weeks should identify
approximately 18 caregivers whose child truly had an episode of
pneumonia at some point within this recall period. This two-week
period prevalence is calculated from a summary estimate of
pneumonia incidence of 300 cases per 1,000 children per year in
low- and middle-income countries based on a systematic review of
population-based cohort studies using standard case definitions
that are consistent with the World Health Organization Integrated
Management of Childhood Illness case definition of pneumonia
[16]. This summary estimate equates to about six new episodes per
week per 1,000 children. Children with new episodes that arise
over a three-week period will have pneumonia symptoms falling
within the two-week period if the child is symptomatic for one
week.
Efforts can then be made to establish whether the children with
pneumonia received appropriate antibiotic treatment. To estimate
a treatment rate of 50% with a precision of 65% (95% confidence
interval of 45%–55%) would require 385 children with pneumonia
to be surveyed, and this in turn would require a survey sample size
of about 20,000 children. Thus, surveys of many thousand
caregivers of young children are required to generate a sufficiently
large denominator of ‘‘children with pneumonia’’ from which to
measure antibiotic treatment rate. The only such surveys that are
conducted widely in low- and middle-income countries at this scale
are the DHS and MICS surveys. Both types of survey collect
information on children with cough accompanied by rapid or
difficult breathing that is due to a problem in the chest. DHS refers
to these children as having ‘‘symptoms of acute respiratory
infection’’; MICS refers to them as ‘‘suspected’’ cases of
pneumonia. Neither of these survey programmes claims that
actual cases of pneumonia are measured through the questions
included in the surveys.
How Well Do Reported Symptoms and Signs of
Pneumonia Indicate the Presence of True
Pneumonia?
We have previously reported that in conditions of low disease
prevalence it is very challenging to obtain an accurate estimate of
the true number of episodes of a condition from a screening test—
in this case eliciting caregiver report of symptoms of pneumonia or
‘‘suspected pneumonia’’ based on clinical signs recognised by the
caregiver (as in DHS and MICS surveys) [17]. For simplicity,
throughout the rest of this paper, we will refer to these as cases of
‘‘suspected pneumonia’’.
Table 1 shows a schematic distribution of cases of ‘‘true
pneumonia’’ (true disease) according to caregiver report of
‘‘suspected pneumonia’’ (reported symptoms) and true disease
status. The sensitivity, specificity, positive and negative predictive
values of the survey (test characteristics), and disease prevalence
can all be calculated from the numbers of children in cells a–d of
this table (see Box 1). As we will now discuss, plausible values of
pneumonia prevalence and of sensitivity and specificity can be
inserted into these 262 tables, and the findings can be used to
better understand the output of DHS and MICS surveys.
Our first example (Table 2) considers a scenario where 1,000
caregivers are surveyed, the test sensitivity is 80%, and the test
specificity is 85%. This corresponds to roughly the level of
sensitivity that has been reported for a trained health worker
assessment of pneumonia at a health centre based on clinical signs
Table 1. Distribution of cases of ‘‘true pneumonia’’ (true
disease) according to caregiver report of ‘‘suspected
pneumonia’’ (reported symptoms) and true disease status.
Reported Symptoms True Disease
Present Absent Total
Present a b
Absent c d
Total
Cell a represents children with ‘‘true pneumonia’’ (true positives) whose
caregiver gave a report of ‘‘suspected pneumonia’’ (test positive). Cell b
represents children without pneumonia (true negatives) whose caregiver gave
a report of ‘‘suspected pneumonia’’ (test positive). Cell c represents children
with ‘‘true pneumonia’’ (true positives) whose caregiver did not give a report of
‘‘suspected pneumonia’’ (test negative). Cell d represents children without
pneumonia (true negatives) whose caregiver did not give a report of
‘‘suspected pneumonia’’ (test negative).
doi:10.1371/journal.pmed.1001421.t001
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but assumes a higher level of specificity than is usually achieved in
these circumstances. It is unlikely that the performance of
caregiver report of ‘‘suspected pneumonia’’ will reach these levels
of sensitivity and specificity, and this scenario is therefore likely to
give an over-optimistic picture of the ability of surveys based on
caregiver report to discriminate true pneumonia. Table 2 illus-
trates that in this scenario there would be 161 reports of
‘‘suspected pneumonia’’ and 18 cases of true pneumonia among
the children of the 1,000 caregivers surveyed—a ratio of reported
‘‘suspected pneumonia’’ to true pneumonia of 8.9:1 (161/18).
Thus, ‘‘suspected pneumonia’’ in this setting is a very inaccurate
measure of true pneumonia frequency. Furthermore, of the 161
cases of ‘‘suspected pneumonia’’ for which the caregiver would be
questioned about receipt of antibiotic treatment, only 14/161
(8.7%, the positive predictive value of the survey tool) would have
true pneumonia, making ‘‘suspected pneumonia’’ a very unreliable
denominator from which to calculate antibiotic treatment rate. If
all 14 children with true pneumonia correctly received antibiotic
treatment and all the cases without true pneumonia correctly did
not receive antibiotic treatment, then this would be recorded as an
antibiotic treatment rate of about 9%, and programme efforts to
substantially increase this rate would only serve to promote the
over-prescription of antibiotics.
It is possible that, due to a different ‘‘case mix’’ (a different
proportion of completely well children) at the household and at the
health centre level, the specificities of ‘‘suspected pneumonia’’ in
household surveys could be higher than those based on clinical
signs recorded by trained health workers at the health centre.
Thus, in Tables 3 and 4, we illustrate examples with higher test
specificities. As the test specificity rises to very high levels (95% and
99%, respectively), the ratio of reported ‘‘suspected pneumonia’’ to
true pneumonia falls to 3.5:1 (63/18) and 1.3:1 (24/18),
respectively—still overestimates of pneumonia prevalence but
much less inaccurate. In addition, as the specificity increases, the
proportion of ‘‘suspected pneumonia’’ that is true pneumonia (the
positive predictive value of the tool) rises to 22% (14/63) and 58%
(14/24), respectively. Thus, maximising test specificity has the
potential to make large improvements to the validity of the
denominator that is used to measure pneumonia treatment rates.
An increase in specificity from 80% to 99% increases the
proportion of ‘‘suspected pneumonia’’ that is truly pneumonia
(the positive predictive value) from less than 9% (Table 2) to
approximately 58% (Table 4).
By contrast, decreasing test sensitivity from 80% to 60% with a
fixed specificity of 95% has only a modest impact on the ratio of
reported ‘‘suspected pneumonia’’ to true pneumonia, which falls
only slightly from 3.5:1 (63/18) (Table 3) to 3.3:1 (60/18) (Table 5).
Moreover, the positive predictive value falls only slightly from 22%
(4/63) (Table 3) to 18% (11/60) (Table 5). Since increasing test
specificity is usually linked to falling test sensitivity, it is clear that
maximising test specificity should be prioritised in the test design.
We will briefly discuss how test specificity might be maximised at
the end of this review.
There are actually very few published reports of the sensitivity
and specificity of caregiver reports of symptoms and signs of
pneumonia for the discrimination of true pneumonia. However,
using the mean estimate of sensitivity (31%) and specificity (91%)
of caregiver report of fast or difficult breathing for prediction of
true pneumonia (diagnosed by a study physician) from two
community-based studies in Gambia [18] and Pakistan [19] would
yield 94 reported cases of ‘‘suspected pneumonia’’ among 1,000
children. This represents a ratio of ‘‘suspected pneumonia’’ to true
pneumonia of 5.2:1 (94/18) and a positive predictive value of only
6.4% (6/94). As discussed elsewhere in this Collection, studies
undertaken in Pakistan and Bangladesh provide additional data
from both hospital-based and community-based studies to further
assess the important issue of detection of true pneumonia [20].
Importantly, as noted earlier, the data on the sensitivity and
specificity of pneumonia reporting that is needed to determine the
prevalence of true pneumonia should ideally come from commu-
nity-based studies because hospital-based clinic studies may
overestimate sensitivity and underestimate specificity due to the
different case mix at the hospital level (pneumonia cases tend to be
more severe on average in hospitals than in the community, and
non-pneumonia cases tend to be less healthy and more likely to
have other causes of difficulty breathing). Moreover, because the
discriminative power of caregiver reports depends largely on
caregiver recognition of symptoms and signs of pneumonia, it is
also likely to be influenced greatly by contextual factors such as the
Box 1. Calculation of Test Characteristics
If we consider the caregiver report of reported symptoms
and signs of pneumonia (referred to below as ‘‘suspected
pneumonia’’) as defined by DHS and MICS survey
guidelines to be a test of true pneumonia status in the
child, then:
N The sensitivity of the caregiver report of ‘‘suspected
pneumonia’’ (test) is given by a/(a+c);
N The specificity of the caregiver report of ‘‘suspected
pneumonia’’ (test) is given by d/(b+d);
N The positive predictive value of the caregiver report of
‘‘suspected pneumonia’’ (test) is given a/(a+b);
N The negative predictive value of the caregiver report of
‘‘suspected pneumonia’’ (test) is given by d/(c+d); and
N The disease prevalence is given by (a+c)/(a+b+c+d).
Table 2. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 80% and specificity is
85%.
Reported Symptoms True Disease
Present Absent Total
Present 14 147 161
Absent 4 835 839
Total 18 982 1,000
doi:10.1371/journal.pmed.1001421.t002
Table 3. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 80% and specificity is
95%.
Reported Symptoms True Disease
Present Absent Total
Present 14 49 63
Absent 4 933 937
Total 18 982 1,000
doi:10.1371/journal.pmed.1001421.t003
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level of maternal education and prior exposure to relevant health
education messages. Thus, the interpretation of trends in antibiotic
treatment data over time will be complicated in settings where
there have been temporal trends in education levels or health
education interventions or where serial surveys have been
conducted in different populations.
Another Strategy for Improving the Positive
Predictive Value of Surveys
In addition to increasing test specificity, another strategy that
should improve the proportion of ‘‘suspected pneumonia’’ reports
that truly represent cases of pneumonia (positive predictive value)
is to increase the disease prevalence detected in DHS and MICS
surveys. This could be achieved by conducting surveys during the
peak pneumonia season. Alternatively, if the recall period were to
be increased from two weeks to four weeks (or eight weeks), then
30 (or 54) reports of pneumonia symptoms and signs would be
expected, rather than 18 reports. Tables 6 and 7 show that with
the same levels of sensitivity (80%) and specificity (95%) as in the
example in Table 3, these longer recall periods would yield 72 (or
90) reported cases of ‘‘suspected pneumonia’’ and 30 (or 54) cases
of true pneumonia among 1,000 children. Thus, the ratio of
‘‘suspected pneumonia’’ to true pneumonia would be about 3:1 (or
1.7:1) (compared to 3.5:1 in Table 3), and the proportion of
‘‘suspected pneumonia’’ that is true pneumonia would be 33% (or
48%) rather than 22% as in Table 3.
If we use the data from Gambia [18] and Pakistan [19] on test
specificity and sensitivity combined with longer recall periods, the
proportion of ‘‘suspected pneumonia that is true pneumonia
(positive predictive value) would rise from 6.4% to 9.8% (or
16.7%) based on four-week (or eight-week) recall, respectively.
Because these predictions are based on the assumption that test
performance would not change with the longer recall period, it will
be important to test this assumption (see [20]) before any such
increase in recall period is introduced into surveys.
A Combined Strategy to Improve the
Identification of True Pneumonia Episodes from
Maternal Report of ‘‘Suspected Pneumonia’’
Finally, we can consider the effect of combining an improved
test specificity and an increased recall period. Using the published
Gambia [18] and Pakistan [19] data, if study recall could be
increased from two to four or eight weeks and test specificity
increased from 91% to 97%, then the proportion of ‘‘suspected
pneumonia’’ that is true pneumonia (the positive predictive value)
would rise by almost an order of magnitude from 6.4% to 23.7%
or 56.9% for four- or eight-week recall, respectively. The field
studies in Pakistan and Bangladesh [20] provide further data from
which to estimate the improvements that could be expected from
attempts to improve survey instruments.
Are DHS and MICS Surveys Suitable Tools for
Monitoring Antibiotic Treatment of Childhood
Pneumonia?
A research priority setting exercise that involved a large number
of doctors from low- and middle-income countries recently listed
improving the community case management of pneumonia and
identifying barriers to and improving access to antibiotic treatment
as among the top research priorities likely to contribute to
achievement of Millennium Development Goal 4 [21]. The
identification of these research priorities reflects the need to reduce
childhood pneumonia if childhood mortality is going to be
reduced, and supports the self-evident need to develop a robust
Table 4. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 80% and specificity is
99%.
Reported Symptoms True Disease
Present Absent Total
Present 14 10 24
Absent 4 972 976
Total 18 982 1,000
doi:10.1371/journal.pmed.1001421.t004
Table 5. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 60% and specificity is
95%.
Reported Symptoms True Disease
Present Absent Total
Present 11 49 60
Absent 7 933 940
Total 18 982 1,000
doi:10.1371/journal.pmed.1001421.t005
Table 6. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 80% and specificity is
95% with a four-week recall period.
Reported Symptoms True Disease
Present Absent Total
Present 24 48 72
Absent 6 922 928
Total 30 970 1,000
doi:10.1371/journal.pmed.1001421.t006
Table 7. Distribution of cases of ‘‘true pneumonia’’ according
to caregiver report of ‘‘suspected pneumonia’’ (test) and true
disease status when test sensitivity is 80% and specificity is
95% with an eight-week recall period.
Reported Symptoms True Disease
Present Absent Total
Present 43 47 90
Absent 11 899 910
Total 54 946 1,000
doi:10.1371/journal.pmed.1001421.t007
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programme indicator—the antibiotic treatment rate—to monitor
local, national, and global progress in increasing the coverage of
this essential pneumonia intervention. Measurement of this
indicator has to be community-based (to capture the many
pneumonia cases that do not attend health services for treatment)
and large (to include enough pneumonia cases to give precise
estimates). DHS and MICS surveys are the only tools that fit these
requirements and that are conducted widely in developing
countries. It is therefore important to assess their suitability for
this purpose, since estimates of pneumonia prevalence and
antibiotic treatment coverage based on these surveys will be
influential in guiding national and international decisions about
programmes to control pneumonia deaths.
The Validity of DHS and MICS ‘‘Suspected Pneumonia’’
Survey Data for the Estimation of the Prevalence of True
Pneumonia
In circumstances of low pneumonia prevalence (such as found
with the two-week recall of pneumonia episodes included in
current surveys), even when the sensitivity and specificity of
‘‘suspected pneumonia’’ as a test for true pneumonia is very high
(.90%), the estimates of the number of pneumonia episodes based
on DHS and MICS survey data will be greatly inflated, and most
reported episodes will be false positives [17]. DHS and MICS
survey questions were not designed to estimate pneumonia
prevalence, and current DHS and MICS guidelines advise against
the use of data in this way. Our review reinforces these
recommendations.
The Validity of DHS and MICS ‘‘Suspected Pneumonia’’
Survey Data for the Estimation of the Antibiotic
Treatment Rate for Pneumonia
The findings we present in this review (Tables 1–7) have
important implications for the use of existing DHS and MICS
survey data in monitoring antibiotic treatment rates. The DHS/
MICS antibiotic treatment indicator for ‘‘suspected pneumonia’’ is
often used as a proxy indicator for a pneumonia treatment
indicator. For this indicator to give accurate information that is
useful for programme planning, we need to have a denominator as
close to true pneumonia as possible. A denominator of ‘‘suspected
pneumonia’’ in which most cases are not true pneumonia makes
interpretation of this indicator problematic, and action based on
adoption of this indicator alone could drive over-prescription of
antibiotics.
It is clear from the examples we work through in this review and
from underlying theory based on known epidemiology of
pneumonia [17] that the discriminative power of survey instru-
ments needs to be improved. This discriminative power is
constrained by the inherent limited ability of caregivers to
correctly recognise and report symptoms and signs of pneumonia.
Within this constraint, it is possible to increase test specificity (at
the expense of test sensitivity) by adding a few additional
symptoms or signs to survey questionnaires that show good
predictive power or by employing a ‘‘pneumonia score’’, as
reported elsewhere in this Collection [20]. In this latter approach,
a survey would include questions about a series of signs or
symptoms of pneumonia, and one mark would be awarded for
each sign or symptom that is reported. A threshold score level
defined by a favourable combination of sensitivity and specificity
levels could then be selected for use. However, it is possible that
the underlying discriminative power of this approach will remain
constrained since it relies on caregiver recognition. One way to
overcome this constraint and to improve overall discriminative
power might be to adopt a new approach for questioning
caregivers that relies on video recognition [20]. Such an approach
would operate via visual recognition memory rather than via
auditory recognition memory, which may promote better recog-
nition and recall [22]. This argument could also be applied to the
measurement of the antibiotic treatment rate indicator. Thus, ‘‘pill
boards’’ or digital formats could be shown to caregivers that
illustrate a range of local drugs, to promote correct recall of
antibiotic prescriptions.
It could be argued that although the interpretation of the
absolute value of the antibiotic treatment rate indicator is very
problematic, there may still be considerable utility in using its
relative value to track trends over time (and to compare across
countries) for programme planning purposes. However, these data
should be interpreted with caution, since contextual factors are
likely to influence results significantly, and these may vary by time
and place independent of trends in antibiotic treatment rates.
The Validity of DHS and MICS ‘‘Suspected Pneumonia’’
Survey Data for the Estimation of Appropriate Care
Seeking for Pneumonia
The care-seeking indicator for ‘‘suspected pneumonia’’ that is
found in DHS/MICS surveys remains valid. ‘‘Suspected pneu-
monia’’ based on simple signs that caretakers can understand and
that programmes can use is an appropriate denominator for this
indicator, as the aim is to encourage all these children to be
assessed by a health provider whether or not they actually have
pneumonia.
Future Research and Prospects
Given the importance of antibiotic treatment rates as a
programme indicator, there is an urgent need for more research
to measure the sensitivity and specificity of ‘‘suspected pneumo-
nia’’ as defined in DHS and MICS surveys for the identification of
true pneumonia episodes. The sensitivity and specificity of
‘‘suspected pneumonia’’ needs to be measured in a range of
Key Points
N Large household surveys are required to identify recent
cases of pneumonia as a denominator from which
antibiotic treatment rates for pneumonia can be
estimated.
N At the low levels of pneumonia prevalence found in
household surveys, most of the children identified with
‘‘suspected pneumonia’’ will not have true pneumonia,
even when survey tools with very high sensitivity and
specificity are used.
N This inflation of the denominator of the antibiotic
treatment rate will make the treatment rate appear
falsely low and could lead to incorrect programme
decision making.
N In theory, the performance of DHS/MICS survey tools can
be improved by increasing test specificity and/or by
increasing pneumonia period prevalence (by increasing
the recall period or by conducting the survey in the peak
pneumonia season), but this prediction needs testing.
N Alternate approaches to measuring the antibiotic
treatment rate should also be considered, including
those that make use of digital formats to facilitate
pneumonia recognition and recall of antibiotic treat-
ment by caregivers.
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settings and with questions based on a range of recall periods from
two weeks to several months, and must also be compared to the
performance of new approaches such as those described above.
Hazir et al. provide some first estimates of these parameters based
on two- and four-week recall and estimate the impact on test
performance of some new survey methods [20]. Consideration
should also be given to the feasibility of including in future surveys
some assessment of whether the prescribed antibiotic was actually
taken correctly by the child.
In addition to optimising existing means of determining
antibiotic treatment rates for pneumonia, recent developments in
eHealth and mHealth (health care supported by electronic
processes and communication and by mobile devices, respectively)
applications in low- and middle-income countries and their use,
for example, in surveillance of influenza episodes [23] may mean
that novel real-time measurement of child health programme
indicators will soon be feasible in some settings. Finally, in the
short term, digital illustrations of local treatments or of children
with signs of pneumonia that are recognised by local caregivers
should be technically feasible and could facilitate accurate data
capture, storage, and transmission for analysis [24], thereby
helping to improve the way we monitor antibiotic treatment
coverage among young children with pneumonia.
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